NCT00814021 2026-04-15
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Institut Claudius Regaud
Phase 2 Completed
Clinical Trials
701 trialsNCT04028245 2026-04-15
SPARC-1
Columbia University
Phase EARLY_PHASE1 Completed
NCT05410509 2026-04-14
"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"
University of Alabama at Birmingham
Phase NA Completed
NCT06020651 2026-04-08
VICKI
Institut Mutualiste Montsouris
Phase NA Completed
NCT03798626 2026-04-01
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
Phase 1 Completed
NCT02555748 2026-03-31
SUP-R
Institut Claudius Regaud
Phase 4 Completed
NCT06108479 2026-03-18
Study of DF6215 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
Phase 1 Completed
NCT06894771 2026-03-16
MK-4700-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT03945773 2026-03-13
CaboPoint
Ipsen
Phase 2 Completed
NCT03142334 2026-03-10
KEYNOTE-564
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT07436416 2026-02-27
EXO-RENAL2
Institute of Oncology Ljubljana
Phase NA Completed
NCT07406646 2026-02-12
EXO-RENAL1
Institute of Oncology Ljubljana
Phase NA Completed
NCT01625351 2026-02-06
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
St. Jude Children's Research Hospital
Phase 1 Completed
NCT02853331 2026-02-02
KEYNOTE-426
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00625755 2026-01-23
A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma
Beth Israel Deaconess Medical Center
Phase 1/2 Completed
NCT06840548 2026-01-13
OncoCAIX
Philogen S.p.A.
Phase 1 Completed
NCT06138496 2026-01-05
Cadonilimab Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Sun Yat-sen University
Phase 2 Completed
NCT04349267 2025-12-17
Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04704219 2025-12-03
KEYNOTE-B61
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT05377632 2025-11-28
PIONEER-OPT
Kantonsspital Baden
Phase NA Completed
NCT05795595 2025-11-26
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
CRISPR Therapeutics
Phase 1/2 Completed
NCT07232927 2025-11-18
HEMOSTA-PN
Ankara University
Phase NA Completed
NCT04374877 2025-11-10
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
Coherus Oncology, Inc.
Phase 1 Completed
NCT02162732 2025-11-03
Molecular-Guided Therapy for Childhood Cancer
Milton S. Hershey Medical Center
Phase NA Completed
NCT05597839 2025-10-29
Study of DF9001 in Patients With Advanced Solid Tumors
Dragonfly Therapeutics
Phase 1/2 Completed
NCT05293496 2025-10-14
A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
MacroGenics
Phase 1 Completed
NCT04169711 2025-10-09
Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma
Arrowhead Pharmaceuticals
Phase 1 Completed
NCT03075423 2025-09-26
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC
Goethe University
Phase 2 Completed
NCT01120249 2025-09-16
S0931
SWOG Cancer Research Network
Phase 3 Completed
NCT04758507 2025-09-08
TACITO
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase 1/2 Completed
NCT00930033 2025-09-05
CARMENA
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT05263245 2025-09-03
Skippy 1
Leiden University Medical Center
Phase 2 Completed
NCT05114668 2025-09-02
Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours
Kazia Therapeutics Limited
Phase 1 Completed
NCT02923349 2025-08-24
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
Incyte Corporation
Phase 1/2 Completed
NCT03948724 2025-08-17
EDHITO
Institut Cancerologie de l'Ouest
Phase NA Completed
NCT03126110 2025-08-14
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Phase 1/2 Completed
NCT03685448 2025-08-08
UNICAB
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Completed
NCT03967522 2025-08-08
CABRAMET
Centre Leon Berard
Phase 2 Completed
NCT05585034 2025-08-07
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Xencor, Inc.
Phase 1 Completed
NCT02903914 2025-08-05
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Incyte Corporation
Phase 1 Completed
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT03260894 2025-07-29
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
Phase 3 Completed
NCT04508725 2025-07-25
Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)
Stanford University
Phase NA Completed
NCT04627064 2025-07-25
ABEMA Alone or in COMBO With MK-6482
Dana-Farber Cancer Institute
Phase 1 Completed
NCT02231749 2025-06-26
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Bristol-Myers Squibb
Phase 3 Completed
NCT05788484 2025-06-15
A Study of CDX-585 in Patients With Advanced Malignancies
Celldex Therapeutics
Phase 1 Completed
NCT05404685 2025-06-13
P-NeLoP
University Hospital, Bordeaux
Phase NA Completed
NCT03297593 2025-06-06
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
Swiss Cancer Institute
Phase 2 Completed
NCT04337970 2025-05-28
Talazoparib and Axitinib for People With Previously Treated Advanced Kidney Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02799095 2025-05-21
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
Mural Oncology, Inc
Phase 1/2 Completed